Taken together, our data support the development of novel rational combinatorial treatment strategies for patients with HER2+ breast cancer and TNBC, such as the strategies that are currently being developed in clinical trials (NCT02400476, NCT03101748). This evidence concerns the gene ERBB2 and breast cancer.